Home  /  Resource Library  /  Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age <65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age <65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

ASH 2020: Results of a phase II trial investigating ibrutinib combined with rituixmab along with short course high dose chemotherapy for front line treatment of MCL.